Home
overview
A unique opportunity to learn from leading industry experts including:

  • Dr Heiner Dreismann, Head, Molecular Diagnostics, Roche Molecular Diagnostics
  • Dr Peter Knueppel, Senior Vice President, Nucleic Acid Diagnostics Segment, Bayer Healthcare
  • Dr Keith Dionne, Vice President, Research & Development Strategy, Millennium
  • Vinod Kaushal, Vice President, Product Strategy, Amersham Health
  • Dr Andrew Heaton, Chief Medical Officer & Vice President, Blood Testing, Chiron
  • Dr Bernd Haase, Business Development Manager, Europe, Affymetrix
  • Dr Hans Jorg Grill, Chief Technology Officer, Business Area, Clinical Diagnostics, Tecan
  • Dr Metin Colpan, Chief Executive Officer, Qiagen
  • Thomas Soriano, President & Chief Executive Officer, Diagnostic Oncology CRO
  • Jan Mous, President & CEO, IntegraGen

    Benefits of Attending

  • MARKET OPPORTUNITES: Identify where the gaps in the market lie
  • TECHNOLOGY PLATFORMS: Evaluate methods being used for molecular diagnostics, including immunoassays, probe-based nucleic acid assays and microarrays
  • PRINCIPLES & APPLICATIONS: Discover chief molecular test areas including early screening, prognostic monitoring and pharmacogenomic testing
  • STRATEGIES: Learn of the practices being utilised by leading diagnostic companies to increase their market share
  • KEY INDUSTRY PERSONNEL: Meet the leaders in the field
  • Conference programme

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Doris-Ann Williams

    Doris-Ann Williams, Director General, British In Vitro Diagnostics Association (BIVDA)

    9:10 KEYNOTE ADDRESS

    Dr Heiner Dreismann

    Dr Heiner Dreismann, Head, Molecular Diagnostics, Roche Molecular Diagnostics

  • The challenge of creating the molecular diagnostics market
  • Identification of current technology trends
  • Review of molecular technology platforms including nucleic acid testing and microarrays
  • Identifying feasible market opportunities through the identification of expanding markets
  • 9:40 MOLECULAR DIAGNOSTICS IN RESEARCH

    Dr James Prudent

    Dr James Prudent, Chief Scientific Officer, EraGen Biosciences

  • Nucleic acid and protein testing
  • Searching for targets – drivers and bottlenecks of HT technologies
  • Linking therapeutics to diagnostics
  • Involvement of bioinformatics
  • Global forecast
  • 10:20 INCORPORATING MOLECULAR DIAGNOSTICS IN A THERAPEUTIC DEVELOPMENT WORLD

    Dr Keith Dionne

    Dr Keith Dionne, Vice President, Research & Development Strategy, Millennium

  • Co-developing therapeutic and diagnostic products
  • Developing molecular diagnostics to support research and development portfolios
  • Developing molecular diagnostics as commercial agents
  • Portfolio impacts of joint therapeutic/diagnostic products
  • 11:00 Morning Coffee

    11:20 CLINICAL APPLICATIONS

    Dr Stephen Little

    Dr Stephen Little, Chief Executive Officer, DxS Ltd

  • Role in predisposition, early screening, prognostic, monitoring and pharmacogenomic testing
  • The diagnostic therapeutic interface
  • Developing innovative business strategies to bridge the gap
  • Tackling regulations, product launch costs and medical acceptance and reimbursement
  • Logistics, samples and technology
  • Long term prospects for clinical diagnostics
  • 12:00 US REGULATION OF MOLECULAR IVD PRODUCTS

    Thomas Soriano

    Thomas Soriano, President & Chief Executive Officer, Diagnostic Oncology CRO

  • FDA Overview
  • Regulations and guidance documents of interest
  • ASRs and “Home Brews”
  • Projected changes in policies and regulations, et al
  • 12:40 Networking Lunch

    13:40 ONE PATIENT…MANY PATENTS

    Brian Voyce

    Brian Voyce, Attorney, VPX LLC

  • A forest of diagnostic patents
  • Interests of the deliverers Vs the discoverers
  • How to blend multiple technology into a single product
  • 14:20 ENHANCING GENE IDENTIFICATION AND ANALYSIS

    Dr Rhiannon Sanders Ph.D

    Dr Rhiannon Sanders Ph.D, Director Market Development, Pyrosequencing AB

  • Applications for DNA-based testing
  • Enhancing drug efficacy and safety
  • Issues in assessing technologies
  • Current technology limitations and opportunities
  • 15:00 REALISING THE POTENTIAL OF COMPANION DIAGNOSTICS

    Angus Hastie

    Angus Hastie, Director, Marketing & Business Development, Roche Molecular Diagnostics

  • Strategies to develop this field to its full potential
  • Prospects for predicting treatment response or adverse reactions using molecular diagnostics
  • Healthcare economic benefits of combining diagnostic testing with pharmaceutical prescription
  • Developing partnerships between diagnostic and pharmaceutical companies
  • 15:40 Afternoon Tea

    16:00 FAST AND RELIABLE DISCOVERY OF DISEASE GENES

    Dr Jan Mous

    Dr Jan Mous, President & CEO, Integragen

  • Genome Hybrid Identity Profiling, a radically innovative gene mapping technology
  • Unmatched statistical power and fast results
  • Proven concept : results of target discovery in complex genetic diseases, like obesity and autism
  • Strategy to identify genetic markers of diagnostic value
  • Demonstrating cost benefits
  • 16:40 RELIABLE AND FLEXIBLE SAMPLE PREPARATION

    Dr Simon Douglas

    Dr Simon Douglas, Chief Executive Officer, DRI Ltd

  • Inhibitor-free DNA for reliable downstream processing
  • Sample preparation designed to meet end user needs
  • Cost effective automation
  • Simplifying NAT with Charge Switch™
  • 17:20 NUCLEIC ACID TESTING (NAT)

    Dr Peter Knueppel

    Dr Peter Knueppel, Senior Vice President, Nucleic Acid Diagnostics Segment, Bayer Healthcare

  • Individualised medicine and nucleic acid testing
  • Overview of the major market segments
  • Qualitative Vs quantitative tests
  • Limitations of NATs
  • The drive towards miniaturisation and automation
  • 18:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Bruce Savage

    Bruce Savage, Managing Director, Cytocell

    9:10 IMPACT OF NAT AND MOLECULAR BIOLOGY DEVELOPMENTS IN A HIGHLY REGULATED BLOOD SAFETY MARKET

    Dr Andrew Heaton

    Dr Andrew Heaton, Chief Medical Officer & Vice President, Blood Testing, Chiron

  • Development of strategic partnerships to pursue blood safety opportunities
  • Application of nucleic acid testing to enhance blood product safety
  • Implementation of accelerated product development to meet blood safety initiatives
  • Application and potential of new technologies to sustain blood safety development
  • Focused product development and customer relationship development
  • 9:40 AUTOMATION – THE KEY TO THE NAT MARKET

    Dr Hans-Jörg Grill

    Dr Hans-Jörg Grill, Chief Technology Officer, Business Area, Clinical Diagnostics, Tecan

  • The role of multi probe assays, biochips and micro fluidics in NAT testing
  • The commercial impact of automation on the market
  • Overcoming the hurdle of automated sample preparation
  • Importance of simplifying diagnostics to penetrate the POC market
  • 10:20 PRE-ANALYTICAL SAMPLE PREPARATION AND AUTOMATION IN MOLECULAR DIAGNOSTICS

    Dr Metin Colpan

    Dr Metin Colpan, Chief Executive Officer, Qiagen

  • Sample collection, stabilization and purification technologies
  • The impact on sample preparation on performance and dynamic range
  • Overcoming the hurdle of automated sample preparation and reaction set up
  • Automation needs and solutions for NAT
  • The drive towards universal integrated solutions
  • 11:00 Morning Coffee

    11:20 THE DIAGNOSTIC MARKET OPPORTUNITIES FOR DNA MICROARRAYS

    Dr Bernd Haase

    Dr Bernd Haase, Senior Business Development Manager, Europe, Affymetrix

  • Signature identification using microarrays
  • RNA expression analysis and its future
  • Novel DNA analysis strategies
  • Patient stratification
  • Regulatory issues
  • 12:00 GENETIC TESTING FOR INFECTIOUS PATHOGENS

    Dr Tom Whitaker

    Dr Tom Whitaker, President & Chief Executive Officer, Atom Sciences

  • Review of the infection disease genetic testing market
  • Importance of increasing speed and reducing cost
  • Significance of being able to identify bacterial drug resistance
  • Analysis of new technologies set to have a major impact on infectious disease testing
  • 12:40 Networking Lunch

    13:40 CASE STUDY: RUBICON GENOMICS

    Dr John Langmore

    Dr John Langmore, Co-Founder & Vice President, Commercial Development, Rubicon Genomics

  • Bioinformatics of genome-wide methylation screens as a critical discovery tool
  • Importance of retrospective and prospective studies
  • Integration of point-of-care genetic, epigenetic, and expression analysis
  • Protocols for early detection of occurrence and recurrence from miniscule amounts of degraded DNA and RNA
  • 14:20 DIAGNOSTIC IMAGING

    Vinod Kaushal

    Vinod Kaushal, Vice President, Product Strategy, Amersham Health

  • Potential of in vivo imaging in personalised medicine
  • Key technologies that will be utilised
  • Disease areas with the greatest commercial propect
  • Demostrating the cost benefits
  • Forming strategic partnerships with the pharmaceutical industry for mutual gain
  • 15:00 APPLIED GENOMICS AND ASSAY DEVELOPMENT

    Jeffrey Walsh

    Jeffrey Walsh, Vice President, Business Development & Strategy, EXACT Sciences

  • What is applied genomics?
  • The fundamentals of an applied genomics development program in cancer
  • A review of the process for developing an assay in molecular diagnostics
  • EXACT Sciences’ model for market-based assay development
  • Colorectal cancer and PreGen Plus
  • 15:40 Afternoon Tea

    16:00 MOLECULAR TESTING IN THE UNDERSTANDING AND TREATMENT OF DISEASE

    Dr Richard Schifreen

    Dr Richard Schifreen, Director,Technology & Market Development, Promega

  • Clinical and analytical drivers for the development of new diagnostic tests
  • Determining the clinical value of new diagnostic tests
  • Integrating diagnostic testing with the development of new therapeutics
  • New business models for delivering diagnostic testing
  • Changing international regulatory models and their impact on the diagnostics industry
  • 16:40 PHARMACOGENOMIC MEASUREMENT OF DRUG EFFICACY

    Prof Steven Wong

    Prof Steven Wong, Director of Clinical Chemistry/Toxicology, Therapeutic Drug Monitoring, Pharmacogenomics & Proteomics / Scientific Director, Toxicology Department, Medical College of Wisconsin / Milwaukee County Medical Examiner’s Office

  • Strategies for developing this infant field of study to its full potential Governmental regulatory agencies perspectives
  • The prospects for testing the responsiveness of a patient to a treatment via DNA based tests
  • Economic benefits of predicting drug toxicity and the targeting of new drugs to the right patients
  • An opportunity to resurrect old drugs which proved toxic to some and not to others
  • Acquisitions of diagnostic tests by pharmaceutical companies
  • 17:20 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.